Finerenone—a non-steroidal, selective mineralocorticoid receptor antagonist that reduced CKD progression and cardiovascular events in patients with diabetic CKD—was also linked to anti-inflammatory potential [28, 43]. This evidence concerns the gene NR3C2 and chronic kidney disease.